Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering-Plough

This article was originally published in The Tan Sheet

Executive Summary

MiraLAX laxative launched in February helped drive Consumer Health Care third-quarter sales up 5% to $273 mil., Schering-Plough reports during Oct. 22 analyst call. The brand is second in its category in the U.S. with a 7% market share, the firm says. Trailing market leader Metamucil in the laxative/stimulant segment, MiraLAX had dollar sales of $12.1 mil. in food, drug and mass retailers for the 13 weeks ended Sept. 30, according to IRI data. MiraLAX was the first Rx-to-OTC switch in the laxatives category in over 30 years (1"The Tan Sheet" Dec. 11, 2006, p. 7). Also driving growth was Claritin (loratadine) with sales up 9% to $104 mil. OTC sales grew 17% to $162 mil., offset by a 33% decline in sun care sales. Adjusted net revenues increased 12% to $3.5 bil. and profit was $713 mil...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS101054

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel